Provide transparent information quickly by Genexine

Accurate and fast delivery of key events and news of growing Genexine

Press Release

Genexine to Present at the 35th J.P. Morgan Healthcare Conference
2016.12.29

Genexine Inc. (KOSDAQ: 095700), a clinical stage biotechnology company developing innovative biologics focused on immuno-oncology and metabolic/autoimmune diseases, today announced that Dr. H. Michael Keyoung, CEO and President of Genexine, will present at the J.P. Morgan 35th Annual Healthcare Conference Emerging Markets Track on January 11th at the Westin St. Francis Hotel, San Francisco. The J.P. Morgan Healthcare Conference is one of the healthcare industry’s biggest events of the year and it brings thousands of investors and executives from around the world to San Francisco.

 

Event: The 35th Annual J.P. Morgan Healthcare Conference Emerging Market Track

Date: January 11th, 2017 3pm (PST)

Location: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA

 

 

 About Genexine

Genexine, Inc., listed on KOSDAQ (095700-KQ) since 2009, is a clinical stage biotherapeutics company focused on immuno-oncology and metabolic/autoimmune diseases. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA vaccine technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH-hyFc) co-developed by Genexine and Handok for both adult and pediatric GHD, currently in multinational phase II trials. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase II in Europe and Korea for Cervical Intraepithelial Neoplasia II/III and plans to enter into Phase 1b/2a trial in cervical cancer with GX-188E in combination Keytruda (anti- PD-1 therapy) of Merck (also known as MSD) 1H of 2017. Currently Genexine is running over 8 clinical trials from Phase I to Phase IIb in Europe and Asia. In addition to Merck (MSD) collaboration, Genexine has strategic partnerships with leading Asian companies such as Shanghai Fosun Pharma, Tasly Pharma, Kalbe Pharma (largest healthcare Indonesian company), and Korean big Pharma companies such as Handok, Green Cross and Yuhan. Founded in 1999, Genexine has over 150 employees and half of them are scientists with MSc or Ph.D. Genexine is located in Pangyo Techno Valley near Seoul, Korea with a branch office in New York.